Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008

Journal of Clinical Oncology

Volumn 33, Issue 1, 2014, Pages 65-73

  Cossetti, Rachel J D ^a   Tyldesley, Scott K ^a   Speers, Caroline H ^a   Zheng, Yvonne ^a   Gelmon, Karen A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; SYSTEMIC THERAPY; BREAST NEOPLASMS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; TRENDS; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TAXOIDS; YOUNG ADULT;

EID: 84920601089     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2461     Document Type: Article

References (68)

1. DeSantis C, Ma J, Bryan L., et al.: Breast cancer statistics, 2013. CA Cancer J Clin 64:52-62, 2014
2. Davidson A, Chia S, Olson R., et al.: Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: A population-based cohort study. CMAJ Open 1:E134-E141, 2013
3. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
4. Punglia RS, Kuntz KM, Winer E.P., et al.: Optimizing adjuvant endocrine therapy in postmeno-pausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 23:5178-5187, 2005
5. Kaufmann M, Rody A: Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 131:487-494, 2005
6. Grunfeld E, Levine MN, Julian J.A., et al.: Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol 24:848-855, 2006
7. Karnon J, Delea T, Johnston S.R., et al.: Cost effectiveness of extended adjuvant letrozole in post-menopausal women after adjuvant tamoxifen therapy: The UK perspective. Pharmacoeconomics 24: 237-250, 2006
8. Anderson WF, Chen BE, Jatoi I, et al.: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121-126, 2006
9. Kennecke HF, Olivotto IA, Speers C, et al.: Late risk of relapse and mortality among postmeno-pausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18:45-51, 2007
10. Brewster AM, Hortobagyi GN, Broglio K.R., et al.: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179-1183, 2008
11. Mook S, Schmidt MK, Weigelt B, et al.: The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21:717-722, 2010
12. Park S, Koo JS, Kim M.S., et al.: Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four bio-markers using immunohistochemistry. Breast 21: 50-57, 2012
13. Perou CM, Sørlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
14. Goldhirsch A, Wood WC, Coates A.S., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al.: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379:432-444, 2012
16. Goldhirsch A, Winer EP, Coates A.S., et al.: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-2223, 2013
17. Jakesz R, Jonat W, Gnant M., et al.: Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005
18. Goss PE, Ingle JN, Martino S, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005
19. Mamounas EP, Jeong JH, Wickerham D.L., et al.: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 26:1965-1971, 2008
20. Regan MM, Neven P, Giobbie-Hurder A, et al.: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
21. Edge SE, Byrd DR, Compton C.C., et al.: (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2009
22. BC Cancer Agency Cancer Management Guidelines: Breast cancer. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Management/default.htm
23. Elwood JM, Godolphin W: Oestrogen receptors in breast tumors: Associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 42:635-644, 1980
24. Cheang MC, Voduc D, Bajdik C., et al.: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phe-notype. Clin Cancer Res 14:1368-1376, 2008
25. Cheang MC, Chia SK, Voduc D, et al.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
26. Wolff AC, Hammond ME, Schwartz J.N., et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
27. Legha SS, Davis HL, Muggia FM: Hormonal therapy of breast cancer: New approaches and concepts. Ann Intern Med 88:69-77, 1978
28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378:771-784, 2011
29. Slamon DJ, Clark GM, Wong S.G., et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
30. Nguyen PL, Taghian AG, Katz M.S., et al.: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
31. Voduc KD, Cheang MC, Tyldesley S, et al.: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010
32. Kneubil MC, Brollo J, Botteri E., et al.: Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol 39:260-265, 2013
33. Mazouni C, Rimareix F, Mathieu M.C., et al.: Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg 205:662-667, 2013
34. Zhang HM, Zhang BN, Xuan L.X., et al.: Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes. Zhonghua Zhong Liu Za Zhi 31:447-451, 2009
35. Metzger-Filho O, Sun Z, Viale G., et al.: Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from International Breast Cancer Study Group trials VIII and IX. J Clin Oncol 31:3083-3090, 2013
36. Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, et al.: Distribution and prognosis of molecular breast cancer subtypes defined by immu-nohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol 130:609-614, 2013
37. Cancello G, Maisonneuve P, Rotmensz N., et al.: Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immuno-histochemically selected subtypes. Breast Cancer Res Treat 127:713-720, 2011
38. Cortesi L, De Matteis E, Cirilli C, et al.: Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: A population-based study on Italian women. Tumori 98:743-750, 2012
39. Joensuu H, Lehtimäki T, Holli K., et al.: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064-1073, 2004
40. Shen Y, Yang Y, Inoue L.Y., et al.: Role of detection method in predicting breast cancer survival: Analysis if randomized screening trials. J Natl Cancer Inst 97:1195-1203, 2005
41. Coldman A, Phillips N: Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ 185:E492-E498, 2013
42. Fisher B, Brown AM, Dimitrov N.V., et al.: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
43. Mamounas EP, Bryant J, Lembersky B., et al.: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
44. Jones SE, Savin MA, Holmes F.A., et al.: Phase III trial comparing doxorubicin plus cyclophosph-amide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
45. Sparano JA, Wang M, Martino S., et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
46. Jones S, Holmes FA, O'Shaughnessy J, et al.: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxo-rubicin and cyclophosphamide: 7-Year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
47. Martín M, Seguí MA, Antón A, et al.: Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363:2200-2210, 2010
48. Coudert B, Asselain B, Campone M., et al.: Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: The 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 17:900-909, 2012
49. Mackey JR, Martin M, Pienkowski T., et al.: Adjuvant docetaxel, doxorubicin, and cyclophosph-amide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72-80, 2013
50. Slamon DJ, Leyland-Jones B, Shak S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
51. Romond EH, Perez EA, Bryant J, et al.: Tras-tuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
52. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
53. Slamon D, Eiermann W, Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
54. Perez EA, Romond EH, Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
55. Dowsett M, Cuzick J, Ingle J., et al.: Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
56. Shah SP, Roth A, Goya R., et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-399, 2012
57. Gelmon K, Dent R, Mackey J.R., et al.: Target-ng triple-negative breast cancer: Optimising therapeutic outcomes. Ann Oncol 23:2223-2234, 2012
58. Masuda H, Baggerly KA, Wang Y, et al.: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19:5533-5540, 2013
59. Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
60. Lehmann BD, Pietenpol JA: Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:142-150, 2014
61. Berry DA, Cirrincione C, Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
62. Davies C, Pan H, Godwin J., et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
63. Gray RG, Rea D, Handley K., et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 5)
64. Chavez-Mac GM, Barlow WE, Gonzalez-Angulo AM, et al.: A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/ NSABP S1207. Cancer Res 72:OT2-2-04, 2012 (suppl 24; abstr)
65. Polley MY, Leung SC, McShane L.M., et al.: An nternational Ki67 reproducibility study. J Natl Cancer Inst 105:1897-1906, 2013
66. Andersen J, Thorpe SM, King W.J., et al.: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26:442-449, 1990
67. Olivotto A, Coldman AJ, Hislop T.G., et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216-222, 1997
68. Olivotto IA, Bajdik CD, Plenderleith I.H., et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330:805-810, 1994